Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15690052 | 0.80 | KDM4E (0.41) | KDM4C | |
| SCHEMBL15539094 | 0.77 | PDE10A (0.40) | — | |
| SCHEMBL15690069 | 0.74 | USP7 (0.30) | — | |
| SCHEMBL15690152 | 0.74 | PDE10A (0.41) | — | |
| SCHEMBL15690090 | 0.72 | PDE4A (0.37) | — | |
| SCHEMBL15110953 | 0.71 | KDM4C (0.34) | KDM4C | |
| SCHEMBL15690088 | 0.71 | CSNK1D (0.39) | — | |
| SCHEMBL16972431 | 0.70 | PDE10A (0.44) | — | |
| SCHEMBL16972558 | 0.70 | PDE10A (0.44) | — | |
| SCHEMBL15690009 | 0.70 | PDE10A (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399985-B2 | (Hetero)aryl imidazoles/pyrazoles for treatment of neurological disorders | HOFFMANN-LA ROCHE INC. (US) | 2019-09-03 | — | — | US | disclosed |
| EP-3099690-B1 | (HETERO)ARYL IMIDAZOLES/PYRAZOLES FOR TREATMENT OF NEUROLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2019-08-28 | — | — | EP | disclosed |
| EP-3099690-A1 | (HETERO)ARYL IMIDAZOLES/PYRAZOLES FOR TREATMENT OF NEUROLOGICAL DISORDERS | F. Hoffmann-La Roche AG (CH) | 2016-12-07 | — | — | EP | disclosed |
| US-20160333018-A1 | (HETERO)ARYL IMIDAZOLES/PYRAZOLES FOR TREATMENT OF NEUROLOGICAL DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2016-11-17 | — | — | US | disclosed |
| WO-2015113980-A1 | (HETERO)ARYL IMIDAZOLES/PYRAZOLES FOR TREATMENT OF NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-08-06 | — | — | WO | disclosed |
| US-20150209345-A1 | COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE | ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) | 2015-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150209345-A1 | COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE | ALDH1A2, CLN6, PLA2G2E | KDM4C 4669/4885 |
| US-10399985-B2 | (Hetero)aryl imidazoles/pyrazoles for treatment of neurological disorders | GRIN2B, MAOB, GRIN2A | KDM4C 2583/4885 |
| US-20160333018-A1 | (HETERO)ARYL IMIDAZOLES/PYRAZOLES FOR TREATMENT OF NEUROLOGICAL DISORDERS | GRIN2B, MAOB, GRIN2A | KDM4C 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.